Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified

[Guide]

"Clinical evidence seems to support that a combination of these two agents as an intensive initial treatment would be effective in patients with severe disease, i.e., disease with a high inflammatory component, or when a fast onset of results is sought. Both ivermectin and doxycycline 40 mg modified-release act on inflammatory pathways, which results in modulation of the production of downstream inflammatory mediators. This could potentially also help patients see results early on in their treatment, which in turn could improve long-term adherence."

Adv Ther. 2016; 33(9): 1481–1501.
Published online 2016 Jul 18. doi:  10.1007/s12325-016-0380-z
PMCID: PMC5020118
Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments
Martin Steinhoff, Marc Vocanson, Johannes J Voegel, Feriel Hacini-Rachinel, and Gregor Schäfer